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correlation was observed than was expected by random chance). Principal components analysis was used to
control for population structure and helped to minimize type I errors, but this was at the expense of
identifying fewer causal variants. A novel multiple regression approach showed promise to handle correlation
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Abstract: 
As part of Genetic Analysis Workshop 17 our group considered the application of novel and 
standard approaches to the analysis of genotype-phenotype association in next-generation 
sequencing data. Our group identified a major issue in the analysis of the GAW17 next-
generation sequencing data, namely that of type I error and false positive report probability rates 
high above those expected based on empirical type I error levels (as high as 50-90%). Two main 
causes emerged: population stratification and “long-range” correlation (gametic phase 
disequilibrium) between rare variants. Population stratification was expected due to a diverse 
sample. Correlation between rare variants was attributable to both random (e.g. nearly 10K of 
25K markers were ‘private’ variants; small sample size of n=697) and non-random causes (more 
correlation was observed than was expected by random chance). Principal components analysis 
was used to control for population structure and helped minimize type I errors but this was at the 
expense of identifying fewer causal variants. A novel multiple regression approach showed 
promise to handle correlation between markers. Further work is needed to first identify best-
practices for the control of type I errors in the analysis of sequencing data; and then to explore 
and compare the many promising new aggregating approaches for identifying markers associated 
with disease phenotypes.  
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Background 
The next-generation sequencing era is upon us. With the advent of this new era we usher in a 
host of questions about the statistical methods with which we will analyze sequencing data. As 
we explore state of the art sequencing analysis and major questions in the field, it is helpful to 
first look back at lessons learned from the analysis of SNP microarray data. 
The methods used to analyze common (e.g. MAF>5%) SNPs measured using SNP 
microarray technology have matured, with a generally accepted set of best practices for analysis 
of SNP microarray data (e.g. checking for HWE, quality control measures, consideration of 
population stratification, consideration of LD between SNP markers, etc.; for a review of best 
practice protocols see Laurie et al. [2010]). Despite these widely accepted best practices, 
however, some common problems have remained. The biggest unresolved problem is arguably 
that of statistical power. Most GWAS studies, to date, report predominantly small effect sizes 
(e.g. median odds ratio (OR) of all reported ORs in the NHGRI GWAS catalog is 1.3; Hindorff 
et al. [2011]).  Single marker association methods can only detect association with the genotyped 
marker and variants in linkage disequilibrium with it, necessitating the genotyping and testing of 
hundreds of thousands to millions of SNPs to provide genome-wide coverage.  Except for very 
strong associations, it is difficult to have sufficient power to identify true associations as 
statistically significant due to the severe penalty imposed by multiple-testing correction 
procedures. For example, to have sufficient (80%) power to find a SNP significant at the genome 
wide level (e.g. 1x10
-7
) with low minor allele frequency (10%) and low population prevalence 
(10%), which increases the risk of disease by 30% for each copy of the risk allele (e.g. OR=1.3; 
additive effect), one would need to have 4700 cases and 4700 controls if the actual ‘causal’ 
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variant was typed, and potentially even more if the risk variant was not typed but in LD with the 
true ‘causal’ variant [Purcell et al., 2003]. 
In an attempt to combat these power problems, some investigators have successfully used 
very large numbers of subjects (i.e. tens to hundreds of thousands) to find association (e.g. 
Lindgren et al. [2009], Speliotes et al. [2010]). However, for many diseases, cohorts of such size 
do not exist. Another approach attempts to aggregate true variant-phenotype associations across 
biologically meaningful sets (e.g., genes or sets of genes/pathways) in order to both intensify the 
strength of association while simultaneously substantially decreasing the number of tests 
conducted. In many ways this field of methods is in its infancy, though has been considered by 
earlier GAWs (e.g. Tintle et al. [2009]) and others (see Wang et al. [2010] for a recent review). 
Interestingly, this class of aggregation methods for SNP microarray data was developed 
to combat similar problems to those observed in the analysis of genome-wide next-generation 
sequencing data: specifically, conducting many tests where each individual test may be for a 
variant showing a relatively weak signal (a function of risk (effect), allele frequency and the 
sample size of the study). To date, a number of methods have been proposed for next-generation 
sequencing data, all of which have a similar motivation: aggregate signals across all, or some, of 
the SNPs within a gene with the idea of intensifying the observed signal, while decreasing the 
number of tests conducted (see Dering et al. [2011] for a review). 
GAW17 provided many participants with their first attempt to analyze genotypes derived 
from next-generation sequencing data, in the context of a simulated phenotype with known 
characteristics. In our group, eleven of twelve participating groups considered approaches to 
aggregating next-generation sequencing variant signals to increase power using a mix of methods 
including (1) those originally developed for common variants (2) those exclusively developed for 
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NGS data and (3) novel extensions of these methods. Additionally, many groups also considered 
the performance of single SNP analyses on next-generation sequencing data, using both 
previously proposed and novel methods. In this summary paper we summarize the main methods 
proposed and individual findings of Group 7 participants, while also painting a broad picture of 
the current state of the field including major lessons learned and open problems that need to be 
resolved. 
 
Methods 
Data  
The data consists of 697 unrelated individuals genotyped at 24,487 autosomal SNPs, all located 
within one of 3205 different genes. Genotypes were called from whole exome reads obtained 
from the 1000 genomes project, including individuals of European (CEU, TSI), Asian (CHB, 
JPT) and African (YRI, LWK) ethnicity. No quality information (e.g. coverage depth, quality 
score) was provided for the genotypes, though Almasy et al. [2011] note the use of imputation 
for missing genotypes. The organizers of GAW17 simulated two quantitative phenotypes (Q1, 
Q2) and a latent liability trait for each individual. These traits were caused by 160 SNPs in 36 
genes, most of which had low MAF (<0.01; 89 singletons) and many of which were in the VEGF 
pathway. All SNPs increased the likelihood of trait values. The latent liability trait, Q1, Q2 and 
Q4 (caused by SNPs not included in the dataset) all positively increased the likelihood of a 
disease phenotype (y/n). Two hundred simulated phenotype replicates were included. A more 
detailed description of the data used for GAW17 is provided elsewhere (Almasy et al., 2011).  
Group 7 participants 
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Eleven separate manuscripts participated in the Group 7 discussion at the GAW 17 workshop. Of 
these, three manuscripts were not submitted for publication [Ling et al., 2011, Peralta et al., 2011 
and Zlojutro et al., 2011, personal communications], while the other eight [Aschard et al., 2011, 
Hu et al., 2011, Nock et al., 2011, Petersen et al., 2011, Scholz and Kirsten 2011, Wang et al., 
2011, Yang et al., 2011, Yang and Gu 2011], plus one paper from Group 3 that joined our group 
after the workshop [Li et al., 2011], are published in the companion BMC Proceedings volume. 
The methods and results from the nine published submissions are summarized using three broad 
categories based on the type of aggregation used. We note that, where appropriate, manuscripts 
used MAF cutoffs of 1% or 5% to classify SNPs as rare; for specific details see the referenced 
manuscripts. 
Gene level aggregations 
Five manuscripts considered various approaches to aggregating SNP variant information 
at the gene level [Aschard et al., 2011, Hu et al., 2011, Li et al., 2011, Scholz and Kirsten, 2011 
and Yang and Gu, 2011]. Here we briefly describe the methods used in these five manuscripts.  
Aschard et al. [2011] compared rare variant signal to common variant signal using standard 
approaches and then also proposed a new test where rare and common variant methods were 
combined using fisher’s combined probability test across genes. Li et al. [2011] used a multi-step 
training, testing and validation strategy, involving a weighted collapsing approach (Dering et al. 
[2011]) to identify genes associated with the disease phenotype and then compared their 
approach to logistic regression and a random forest. Scholz and Kirsten [2011] compared a 
variety of gene-aggregation approaches including: the maximum statistic of all SNPs within a 
gene, Hotelling’s test, multivariate analysis and Lasso after collapsing all rare variants. Hu et al., 
[2011] applied their genetic risk score approach at both the gene and pathway level (described 
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more fully in the next section). Lastly, Yang and Gu [2011] applied unweighted and weighted 
collapsing strategies (Dering et al. [2011]) at the gene level, in addition to doing pathway 
analyses as described in the next section. 
 
Pathway level aggregations 
Five members of our group considered approaches to aggregating SNP variant information at the 
pathway or gene set level. There were two main types of approaches considered: intermediate 
summarization (SNP level data is first summarized at the gene level using a gene-level 
aggregation method and then aggregated to the pathway level) and direct summarization (SNP 
variant information is summarized directly to the pathway/gene-set level). Two groups 
considered a direct summarization approach [Hu et al., 2011 and Yang et al., 2011], two groups 
considered an intermediate summarization approach [Yang and Gu, 2011 and Nock et al., 2011] 
and one group considered both (Petersen et al., 2011). Groups used a mix of true biological 
pathways from KEGG [Hu et al. 2011], chromosome based sets [Yang et al. 2011] and 
synthetically created sets of genes containing known numbers of truly causal genes [Nock et al., 
2011, Petersen et al. 2011, Yang and Gu, 2011]. 
Intermediate summarization 
Yang and Gu [2011] and Petersen et al. [2011] used published intermediate summarization 
methods adapted for next-generation sequencing data. Namely, they first aggregated SNP scores 
to genes using the weighted and unweighted collapsing strategies (described earlier) and then 
applied GSEA [Yang and Gu 2011, Petersen et al.], VSEA [Yang and Gu], K-S [Petersen et al.] 
and Fisher’s combined probability test [Petersen et al.] using simulated and/or real gene sets. 
Nock et al. [2011] first identified potentially interesting genes using regression and gene-level 
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aggregation. Then, latent variables were constructed to evaluate the aggregate effects of rare and 
common variants in potentially interesting genes. Finally, a structural equation model was used 
to model relationships between genes, covariates and other constructs. 
Direct summarization 
The three groups that used a direct summarization strategy each used different methods. Hu et al. 
[2011] counted the total number of rare variants possessed by each individual across all SNPs 
within a given pathway, comprising an individual’s genetic risk score for that pathway which 
was regressed onto each phenotype separately. Petersen et al. [2011] also used a direct 
summarization strategy, whereby they apply weighted and unweighted collapsing strategies (see 
Dering et al. [2011]) directly to sets of SNPs defined by pathways/gene sets instead of genes. 
Yang et al. [2011] used weighted and unweighted collapsing methods, along with a novel 
variation on the weighted strategy that tunes the weights empirically using the observed 
association with the phenotype.  
No aggregation 
Wang et al. [2011] did not consider aggregation, but instead first applied a simple regression 
model for each SNP. Top ranked SNPs were then subjected to sliced inverse regression (SIR; 
dimension reduction technique). 
False positive report probability and type I error rate 
Most members of our group computed either the false positive report probability (percent of non-
causal genes (or SNPs or pathways) among all genes (causal and non causal) that meet an 
arbitrary criterion for significance; the probability the null is true given that one has rejected the 
null) or the type I error rate (percent of all non-causal genes (or SNPs or pathways) that meet an 
arbitrary criteria for significance among all non causal genes (significant and non-significant); 
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the probability that one rejects the null given that the null is true) as part of their analysis. We 
note that we use the terms “type I error” and “power” in this manuscript rather liberally as their 
utilization across papers in our group varied, including estimates of these quantities across the 
200 phenotype replicates, which all contain the same genotypes. 
Results  
Inflated false positives for gene level aggregations 
All five groups using gene level aggregation reported higher than expected type I error or false 
positive report probabilities.  Specifically, Hu et al. [2011] found a false positive report 
probability of 50% (2/4), Scholz and Kirsten [2011] had a false positive report probability that 
ranged between 94-98% and Li et al. found 8/10. Type I error rates were also inflated (Yang and 
Gu 8-11%; Aschard 9-20%) at the nominal 5% level. A variety of attempts at fixing the problem 
took place including the elimination of genes/SNPs showing spurious (see Luedtke et al. [2011]) 
association (Yang and Gu 2011, Scholz and Kirsten), use of principal components (Aschard et al. 
[2011]), genomic control (Aschard et al. [2011]) and pooling data across phenotype replicates 
[Li et al., 2011]. 
 
Inflated false positives for pathway level aggregations 
Similarly, all five groups applying a pathway level approach found inflated type I error rates.  
Specifically, false positive report probability tended to be quite high (13/20 Yang et al. [2010], 
60.3% for Nock et al. [2011], and 62/72 and 1/3 for Hu et al. [2011]. Type I error rates were also 
inflated (5-9% Yang and Gu; Petersen et al. (up to 50%)). Eliminating spurious genes [Petersen 
et al. 2011 and Yang and Gu 2011] showed substantial improvement in error rates. Using 
principal components did control the type I error rate but no significantly associations remained.  
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Inflated false positives for non-aggregating analysis 
Wang et al. [2011] looked first at the 30 most significant SNPs after application of a regression 
technique on the first 10 replicates and found that 80% of them were false positives. After the 
application of their dimension reduction approach using SIR, the average false positive report 
probability dropped to 20% (4 out of 5 markers selected are causal). 
 
Comparative results of aggregation approaches 
The following sections provide a comparative analysis of the various aggregation approaches. 
All manuscripts are considered except two groups which proposed novel approaches [Nock et 
al., 2011 and Wang et al., 2011] that were not directly compared to existing approaches. 
 
Gene level aggregation 
Aschard et al. [2011] found that collapsing was outperformed by traditional multivariate 
approaches in gene-based association tests, and showed weak power (9-23%) after controlling 
the type I error rate using genomic control as long as a gene included common variants 
(MAF>1%). However, importantly, this power was essentially zero when considering genes that 
included only rare variants. While Li et al. [2011] did not explicitly control the type I error rate, 
they used an ROC curve to compare methods, finding that a novel extension of the Empirical 
Bayes Risk Prediction model provided the highest AUC (area under the curve). Scholz and 
Kirsten [2011] compared methods and found that genes with multiple independent causal 
variants were better detected by multivariate methods (after collapsing rare variants), whereas 
genes with a single causal variant were better detected using the maximum association statistic 
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within a gene; findings that were true regardless of the methods applied to control the type I error 
rate.  
 
Comparing gene and pathway level aggregation 
Hu et al. [2011] and Yang and Gu [2011] explored multiple levels of aggregation and both found 
that aggregating directly to the pathway level yielded more power than first aggregating at the 
gene level.  
 
Pathway level aggregation 
Among groups that compared different pathway level aggregation methods, Yang and Gu [2011] 
found that the novel VSEA method outperformed the standard GSEA method. Petersen et al., 
found that, when summarizing significance at the gene level first, Fishers combined probability 
test outperformed GSEA and the K-S approach, while direct application of the weighted-sum 
method on all SNPs from the pathway tended to yield the most power. Yang et al. [2011] had 
preliminary evidence that MCMC may outperform the genetic algorithms (GA) they considered, 
but they acknowledge that this could be due to particular choices made about the implementation 
of the GA procedures. 
 
Discussion 
In general, Group 7 participants observed very highly inflated Type I errors (as high as 50%), 
high false positive report probabilities (up to 90%) and low power to detect the simulated causal 
variants.  Even after attempts to control type I errors (e.g. correcting for population 
stratification), power was generally quite low. One exception that resulted in high power was the 
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results of collapsing methods (pathway or gene level) where the collapsed variants include a very 
high proportion of causal variants with higher MAF (e.g. FLT1 and KDR). Since only non-
synonymous SNPs predicted by SIFT [Ng and Henikoff, 2001] were included in the causal 
model, reducing the analysis to only non-synonymous SNPs was thought to improve power, 
though results showed only modest improvement [Scholz et al., 2011, Luedtke et al., 2011].   
Two main reasons for Type I errors were addressed during our group discussions and in 
our papers: population stratification and correlation between markers, which we will briefly 
describe in the following sections. 
Population stratification 
When the first round of rare variant collapsing methods were proposed and published, little was 
made of the issue of population stratification. While the treatment of population stratification and 
covariates is a reasonably straightforward issue in regression based approaches on SNP 
microarray data (common variants), little has been published on best practices for handling 
population stratification in next-generation sequencing data. The level of population stratification 
in this sample was large since subjects were taken from 6 populations. Many members of our 
group considered population stratification in their analysis most commonly through the use of 
principal components. In general, this reduced the type I error rate, however many group 
members still saw increased type I errors even after accounting for population stratification. 
Correlation between markers 
In the analysis of SNP microarray data, understanding and leveraging marker correlation is a 
critical part of the design and analysis of most studies, with most of the effort involving linkage 
disequilibrium (correlation of markers generally located in close proximity on the genome). 
However, collapsing and aggregating methods should not be impacted much by LD when 
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aggregating at the gene or pathway level unless there is LD between genes or between pathways, 
something that is usually assumed to be a relatively small problem [Li and Leal, 2008], though it 
is unclear if rare variant methods correctly account for LD blocks within genes/sets. In the data 
considered for this workshop, however, there appears to be correlation between markers, genes 
and pathways that are located far apart on the genome. For example, one of the causal variants 
(private variant C4S1877) is identical to 27 other SNPs in different genes. In another case, 
BUD13 (identified by both Li et al. [2011] and Luedtke et al. [2011]) was a non-causal gene 
showing strong association with Q1 and contained a SNP that was strongly correlated with a 
causal SNP in KDR (r=-0.20, p=9x10
-8
). This correlation between markers that are located far 
apart in the genome is not LD in the truest sense, and was identified as either long-range 
correlation or gametic phase disequilibrium at the workshop. There are two possible explanations 
for the observed correlations: random and non-random causes. 
Random correlation between markers is a phenomenon that is unique to rare variants in 
next-generation sequencing data. For example, the chance that two randomly selected markers 
are perfectly correlated decreases as the allele frequency increases. As noted earlier, when a large 
number of private variants are in a sample (e.g. 9433 on 697 individuals), most private variants 
are perfectly correlated with many other private variants (the 9433 markers were distributed 
across 685 individuals, yielding only 685 distinguishable markers). Random correlation between 
markers is typically not an issue in analysis of common variants. 
Another explanation is non-random correlation. In follow-up analyses both Luedtke et al. 
[2011] and Aschard et al. [2011] demonstrated that correlations between SNPs were significantly 
beyond what is expected due to random chance alone (detailed results not shown). Further 
information on data production and cleaning would be needed to explain the cause of non-
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random correlation between genotypes. Regardless of the cause, few methods have been 
proposed that handle correlated markers for next-generation sequencing data. One such approach 
with promising results has been proposed by Wang et al. [2011], in which they suggest using a 
multiple regression approach of individual correlated SNPs on the phenotype to identify SNPs 
with the strongest marginal effect (detailed results available from the authors). 
Where we stand now 
When type I errors are not well-controlled, evaluation of power becomes meaningless; thus, our 
group has little ability to report on the relative value of various methods in terms of statistical 
power. However, two themes are worth noting. First, as corroborated by a number of groups 
using a variety of approaches, optimal analysis methods are very dependent upon number, 
strength and MAF of markers associated with disease. In this dataset, a few markers with 
MAF>1% had strong association with the phenotype, and so were able to be found by many 
groups, across replicates, using SNP-based, gene-based or pathway-based approaches. In fact, 
SNP-based methods showed some value for these SNPs since the signal is so strong that it 
remains significant even after applying very stringent correction. However, groups struggled to 
detect markers with lower MAF and weaker effects, especially for those genes containing few 
causal SNPs. Pathway methods lend a partial solution, however high (>50%) power is only 
observed when sets of genes contain a large fraction of causal genes: it is unclear if this will be 
the case in practice. Second, as is often the case with a major new technological breakthrough, 
there are a host of good and promising ideas about how to analyze next-generation sequencing 
data, and there were many novel, interesting and still promising approaches proposed by the 
members of our group. Unfortunately, we can make few conclusive statements about many of the 
approaches due to inflated type I errors.  
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Conclusions 
As we saw with the advent of the analysis of SNP microarray data a decade ago, as we enter the 
next-generation sequencing era there are more questions and ideas than there are concrete 
answers about best-practices for the analysis of these data. However, our groups have identified a 
major issue in the analysis of the GAW17 next-generation sequencing data, namely that of type I 
errors and false positive probabilities high above those expected based on empirical type I error 
levels. Certain themes emerged as best practices for the handling of this type I error problem 
including the use of principal components analysis to control for population structure.  
Additionally, multiple groups found evidence of correlation between markers located far apart in 
the genome attributable to both random and non-random causes. While no conclusive statements 
can be made, control of population structure and evaluation of random and non-random 
correlation between markers may help to control inflation of type I errors. Further work is 
needed to first identify best-practices for the control of type I errors in the analysis of next-
generation sequencing data, and then to explore and compare the many promising new 
approaches for identifying markers associated with disease phenotypes.  
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